AR068897A1 - Inhibidores de proteasoma - Google Patents
Inhibidores de proteasomaInfo
- Publication number
- AR068897A1 AR068897A1 ARP080104517A ARP080104517A AR068897A1 AR 068897 A1 AR068897 A1 AR 068897A1 AR P080104517 A ARP080104517 A AR P080104517A AR P080104517 A ARP080104517 A AR P080104517A AR 068897 A1 AR068897 A1 AR 068897A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- group
- aliphatic
- unsubstituted
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
También proporciona composiciones farmacéuticas que comprenden los compuestos de la presente y métodos usando las composiciones en el tratamiento de cáncer. Reivindicacion 1: Un compuesto de la formula (1) o una sal farmacéuticamente aceptable o anhídrido de ácido boronico del mismo, caracterizado porque: P es hidrogeno o una porcion que bloquea un grupo amino; Ra es un grupo alifático C1-4 o fluoroalifático C1-4 que es substituido con 0-1 RA; o Ra y Rb se toman junto con el átomo de carbono al cual se enlazan, formando un grupo cicloalifático de 3 hasta 6 miembros substituido o no substituido; RA es un anillo aromático o cicloalifático substituido o no substituido; Rb es un grupo alifático C1-4 o fluoroalifático C1-4; o Ra y Rb, se toman junto con el átomo de carbono al cual se enlazan, formando un grupo cicloalifático de 3 hasta 6 miembros substituido o no substituido; Rc es un grupo alifático C1-4 o fluoroalifático C1-4 que es substituido con 0-1 RC; RC es un anillo aromático o cicloalifático substituido o no substituido; y Z1 y Z2 son cada uno independientemente hidroxi, alcoxi, ariloxi, o aralcoxi; o Z1 y Z2 juntos forman una porcion derivada de un agente formador de complejos de ácido boronico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/974,758 US7838673B2 (en) | 2007-10-16 | 2007-10-16 | Proteasome inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068897A1 true AR068897A1 (es) | 2009-12-16 |
Family
ID=40534826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104517A AR068897A1 (es) | 2007-10-16 | 2008-10-16 | Inhibidores de proteasoma |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7838673B2 (es) |
| AR (1) | AR068897A1 (es) |
| CL (1) | CL2008003041A1 (es) |
| TW (1) | TW200927145A (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201600029PA (en) | 2004-03-30 | 2016-02-26 | Millennium Pharm Inc | Synthesis of boronic ester and acid compounds |
| CN105237621A (zh) | 2005-11-09 | 2016-01-13 | 欧尼斯治疗公司 | 用于酶抑制的化合物 |
| EP2041158B1 (en) | 2006-06-19 | 2013-04-17 | Onyx Therapeutics, Inc. | Peptide epoxyketones for proteasome inhibition |
| CL2008002966A1 (es) | 2007-10-04 | 2010-06-25 | Onyx Therapeutics Inc | Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros. |
| EA035100B1 (ru) | 2008-10-21 | 2020-04-28 | Оникс Терапьютикс, Инк. | Комбинированная терапия с применением пептид эпоксикетонов |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
| WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| US9359398B2 (en) | 2010-03-01 | 2016-06-07 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| US9061037B2 (en) * | 2010-03-18 | 2015-06-23 | Innopharma, Inc. | Stable bortezomib formulations |
| US8263578B2 (en) | 2010-03-18 | 2012-09-11 | Innopharma, Inc. | Stable bortezomib formulations |
| BR112012025264A2 (pt) | 2010-04-07 | 2019-09-24 | Onyx Therapeutics Inc | inibidor de imunoproteassoma de e´poxicetona peptídica cristalina. |
| AU2011255647A1 (en) | 2010-05-18 | 2012-11-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| CN102391147B (zh) * | 2011-09-27 | 2014-03-26 | 中国农业大学 | 芳甲酰氨基环丙酸的制备和活性 |
| UY34897A (es) | 2012-07-09 | 2014-01-31 | Onyx Therapeutics Inc | Profarmacos de inhibidores peptidicos de expoxi cetona proteasa |
| CN111410663B (zh) * | 2019-01-08 | 2022-11-08 | 北京桦冠医药科技有限公司 | 双靶点协同作用化合物的制备及其在多发性骨髓瘤相关疾病领域的应用 |
| CN114072413B (zh) * | 2019-07-08 | 2024-04-16 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白抑制剂及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
| EP0315574A3 (de) | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
| US5159060A (en) | 1988-05-27 | 1992-10-27 | Mayo Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
| DE3827340A1 (de) | 1988-08-12 | 1990-02-15 | Hoechst Ag | Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| FR2745288B1 (fr) | 1996-02-27 | 1998-04-17 | Adir | Nouveaux derives de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU5788800A (en) | 1999-07-07 | 2001-01-22 | Du Pont Pharmaceuticals Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
| US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
| AU2002243646B2 (en) | 2001-01-25 | 2006-06-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Formulation of boronic acid compounds |
| US20060084592A1 (en) | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| SG10201600029PA (en) | 2004-03-30 | 2016-02-26 | Millennium Pharm Inc | Synthesis of boronic ester and acid compounds |
| EP1863513A2 (en) | 2005-03-11 | 2007-12-12 | The University of North Carolina at Chapel Hill | Potent and specific immunoproteasome inhibitors |
| WO2007005991A1 (en) | 2005-07-05 | 2007-01-11 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein alpha |
| EP1973548A4 (en) | 2005-12-19 | 2010-02-24 | Tufts College | LIGHT PROTEASES INHIBITORS AND THEIR LIGHT PROFORMS |
| JP2009524681A (ja) | 2006-01-27 | 2009-07-02 | フェノミックス コーポレーション | Ｃ型肝炎ウイルスセリンプロテアーゼインヒビターおよびそのための使用 |
-
2007
- 2007-10-16 US US11/974,758 patent/US7838673B2/en active Active
-
2008
- 2008-10-14 CL CL2008003041A patent/CL2008003041A1/es unknown
- 2008-10-15 TW TW097139571A patent/TW200927145A/zh unknown
- 2008-10-16 AR ARP080104517A patent/AR068897A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7838673B2 (en) | 2010-11-23 |
| TW200927145A (en) | 2009-07-01 |
| US20090099132A1 (en) | 2009-04-16 |
| CL2008003041A1 (es) | 2009-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068897A1 (es) | Inhibidores de proteasoma | |
| AR067824A1 (es) | Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer. | |
| EA201170527A1 (ru) | Фармацевтические композиции, включающие соединения бороновой кислоты | |
| RU2011139107A (ru) | Специфические соединения диарилгидантоина и диарилтиогидантоина | |
| AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
| AR080863A1 (es) | Derivados del acido1-amino-2-ciclopropiletilboronico, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer. | |
| AR075090A1 (es) | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. | |
| NO20090328L (no) | Nye forbindelser 385 | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| EA201500265A1 (ru) | Ингибиторы репликации вирусов гриппа | |
| MD4575C1 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| EA201490477A1 (ru) | Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина | |
| AR060429A1 (es) | Compuestos de tioxantina y composicion farmaceutica en base a dichos compuestos | |
| EA201001682A1 (ru) | Производные фенил- и бензодиоксинилзамещенных индазолов | |
| AR054890A1 (es) | Derivados de quinolina como agentes antibacterianos | |
| MX2010003868A (es) | Cis-imidazolinas quirales. | |
| AR084433A1 (es) | Inhibidores de la faah y composiciones farmaceuticas que los contienen | |
| CY1109366T1 (el) | Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης | |
| EA201171415A1 (ru) | Ингибиторы белков семейства iap | |
| EA201490544A1 (ru) | Препараты и лекарственные формы на основе окисленных фосфолипидов | |
| MY160603A (en) | Stabilized lipid formulation of apoptosis promoter | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| EA201491994A1 (ru) | Способы комплексообразования с циклодекстринами для введения пептидных протеасомных ингибиторов в фармацевтические составы | |
| PH12016500034A1 (en) | New isoindoline or isoquinoline compounds, a process for their preparation and phramaceutical compositions containing them | |
| SE0501903L (sv) | Borföreningar användbara vid BNCT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |